Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

Ph 2/3 trial of 2L+ KN026 + chemo in HER2-positive gastric/GEJ cancer met the primary endpoint of PFS at interim analysis

May 6, 2025

Efti + KEYTRUDA Combo Drives Strong OS in Head and Neck Cancer with CPS <1

May 6, 2025

Full Results Announced From Completed Ph 1 Study of JNJ-1900 (NBTXR3) in Pancreatic Cancer

May 6, 2025

CR achieved after 1 month of the in vivo CD19 CAR-T treatment, with durable response sustained over three months in R/R DLBCL patients

May 6, 2025

Higher Exposure of AFM24 Associated with Significantly Higher Response Rates and PFS in Refractory NSCLC Patients

May 6, 2025

Tuspetinib-based Triplet regimen in 1L AML Patients in Ph 1/2 TUSCANY Trial Demonstrates Safety, Complete Remissions

May 6, 2025

Positive Immune Response Data Announced from FLAMINGO-01 Ph 3 Trial

April 30, 2025

Initial Data from Ph 3 Trial Demonstrating 75% CRR at 3 Months with nadofaragene firadenove) in BCG-unresponsive Japanese NMIBC Patients Announced 

April 30, 2025

Ivonescimab + Chemo combo yields Statistically Significant PFS vs. Tislelizumab + Chemo in Chinese Patients with 1L Squamous NSCLC in HARMONi-6 Study

April 30, 2025

Sasanlimab Combination Significantly Improves EFS in BCG-Naïve, High-Risk NMIBC, but misses OS endpoint

April 30, 2025

Positive Interim Ph 2 Results for NP137 in combination with anti-PD(L)1 Announced

April 30, 2025

Positive Interim Results Demonstrating Durable Responses in Ongoing Ph 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC Announced

April 30, 2025

Updated 18-Month Data from Ph 1 Ovarian Cancer Trial with Radspherin Reported

April 30, 2025

New long-term PFS data projections reinforce SC DARZALEX quadruplet therapy as a foundational SoC for patients with newly diagnosed multiple myeloma

April 30, 2025

TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC

April 30, 2025

TAR-200 monotherapy demonstrates highest CRR reported to date with sustained clinical benefits in patients with certain types of bladder cancer

April 30, 2025

Trodelvy + Keytruda Demonstrate Statistically Significant PFS Improvement in Patients With 1L PD-L1+ Metastatic TNBC

April 30, 2025

OLYMPUS Long-Term Follow-Up shows Nearly 4-Year DoR in Patients with LG-UT Urothelial Cancer Who Achieved a Complete Response to prior JELMYTO Treatment

April 30, 2025

Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec announced

April 30, 2025

FAILED TRIAL: ASPEN-03 and ASPEN-04 Ph 2 Trials of Evorpacept + Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

April 30, 2025

Interim OS Analysis Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab vs Keytruda in PD-L1+ve Advanced NSCLC from HARMONi-2 Study

April 30, 2025

TAR-200 monotherapy shows highest complete response with sustained benefits in 12-month data from Ph 2b SunRISe-1 study (Cohort 2) in NMIBC patients

April 22, 2025

Enhertu + pertuzumab in DESTINY-Breast09 Ph 3 trial demonstrated PFS improvement in vs THP as a 1L treatment for patients with HER2-positive metastatic breast cancer

April 22, 2025

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

April 22, 2025

Preliminary results from Ph 2 IPAX-Linz study of TLX101 (131I-iodofalan1) in recurrent high-grade glioma announced

April 22, 2025
Page1 Page2 Page3 … Page29

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.